open access

Vol 52, No 4 (2021)
Review article
Submitted: 2021-07-29
Accepted: 2021-07-29
Get Citation

New opportunities in immunotherapy in multiple myeloma

Dominik Dytfeld1
DOI: 10.5603/AHP.2021.0070
·
Acta Haematol Pol 2021;52(4):371-374.
Affiliations
  1. Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland

open access

Vol 52, No 4 (2021)
REVIEW ARTICLE
Submitted: 2021-07-29
Accepted: 2021-07-29

Abstract

Immunotherapy is a rapidly developing field of multiple myeloma, a disease which despite the development of new drugs remains incurable. There are several antigens that are being assessed in preclinical and clinical settings, but the most studied of all is B-cell maturation antigen (BCMA). BCMA is a target for antibody conjugated with toxins (ADCs), bispecific engagers (BITEs), and modified autologous lymphocytes (CAR-T, chimeric antigen receptor T cells). Belantamab mafodotin (ADC, registered in the European Union), teclistamab (BITE) and two CAR-Ts: ide-cel (Food and Drug Administation-approved) and cilta-cel are the most studied therapies in myeloma. Immunotherapy will definitely change the treatment strategy of multiple myeloma and accelerate the fight against myeloma.

Abstract

Immunotherapy is a rapidly developing field of multiple myeloma, a disease which despite the development of new drugs remains incurable. There are several antigens that are being assessed in preclinical and clinical settings, but the most studied of all is B-cell maturation antigen (BCMA). BCMA is a target for antibody conjugated with toxins (ADCs), bispecific engagers (BITEs), and modified autologous lymphocytes (CAR-T, chimeric antigen receptor T cells). Belantamab mafodotin (ADC, registered in the European Union), teclistamab (BITE) and two CAR-Ts: ide-cel (Food and Drug Administation-approved) and cilta-cel are the most studied therapies in myeloma. Immunotherapy will definitely change the treatment strategy of multiple myeloma and accelerate the fight against myeloma.

Get Citation

Keywords

immunotherapy, CAR-T, bispecific antibodies

About this article
Title

New opportunities in immunotherapy in multiple myeloma

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 4 (2021)

Article type

Review article

Pages

371-374

DOI

10.5603/AHP.2021.0070

Bibliographic record

Acta Haematol Pol 2021;52(4):371-374.

Keywords

immunotherapy
CAR-T
bispecific antibodies

Authors

Dominik Dytfeld

References (12)
  1. Malek E, de Lima M, Letterio JJ, et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 2016; 30(5): 341–348.
  2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024): 1565–1570.
  3. Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013; 62(1): 39–49.
  4. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7): 621–631.
  5. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018; 379(19): 1811–1822.
  6. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21(2): 207–221.
  7. Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020; 38(8): 775–783.
  8. Usmani SZ, Mateos MV, Nahi H, et al. Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). J Clin Oncol. 2020; 38(15_suppl): 100.
  9. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8): 705–716.
  10. Madduri D, Berdeja J, Usmani S, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. Blood. 2020; 136(Suppl 1): 22–25.
  11. Mailankody S, Matous J, Liedtke M, et al. Universal: an allogeneic first-inhuman study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma. Blood. 2020; 136(Suppl 1): 24–25.
  12. Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020; 135(15): 1232–1243.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl